Published on April 29, 2026
mbiomics GmbH, a Munich-based techbio venture, was operating within the burgeoning field of microbiome therapeutics, focusing on innovative solutions for cancer treatment. The company has made notable strides in developing a live bacterial product aimed at enhancing immune checkpoint inhibitors, which currently represent a significant component of cancer therapies.
- TikTok Pulls AI Video Summaries After Major Inaccuracies
- Manus Aims for $1 Billion to Undo Meta Acquisition After Chinese Intervention
- Eufy Unveils Game-Changing Local AI for Home Security
- From Dull to Dazzling: How a Smart Lamp Transformed My Space
- Mark Zuckerberg's AI Clone Could Revolutionize Workplace Communication
- Trump Administration Engages with Anthropic on AI Model Expansion